Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 1996

View Archived Issues

New antibacterial agents under study at Bayer

Reversible cysteine protease inhibitors reported by Arris

PDE IV inhibitors reported by E. Merck

Natural antiplatelet agent discovered at Kitasato Institute

Natural farnesyltransferase inhibitors from Kitasato Institute

NEP inhibitors claimed by Santen

Company profile: MediGene

Novel anticonvulsant described by SmithKline Beecham

Potent, orally active antiplatelet agent discovered by Merck & Co.

Merck & Co. reports nonpeptide fibrinogen antagonists with oral activity

Asian distribution agreement signed for Advanced Magnetics' liver contrast agent

rhBMP-2 cleared for limited clinical trial for spine fusion

Cortecs, Inflazyme collaborate on tests for TB

Disappointing results reported for genital herpes vaccine

Zeneca submits antimigraine Rx for approval

Antimicrobial ranalexin peptides available for licensing

Purified or recombinant TAP 29 with anti-HIV activity available for licensing

Exclusive worldwide rights offered for human full-length TRK-B

Diagnostic kits for beta-thalassemia available for licensing

Cancer diagnostic based on p53 offered for licensing

Exclusive worldwide rights offered for peptide-cleaving endopeptidase

Novel vaccine delivery system available for licensing

Licenses available for lung function monitor

Intracardiac illuminator offered for licensing

Canadian scientists identify new target for respiratory drugs

New 5-FU formulation reduces toxicity in mice

Another European market introduction for Epivir

New market introduction for antiestrogen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...